Presence of a KRAS mutation has been reported as a negative predictive factor in non-small cell lung cancer and is known to limit the efficacy of targeted therapy directed against epidermal growth factor receptor (EGFR) in colorectal cancer (CRC)5. This evidence concerns the gene KRAS and colorectal carcinoma.